Trastuzumab rezetecan

瑞康曲妥珠单抗

Report date: 2026/05/15 20:01:45

Base Information

Drug NameTrastuzumab rezetecan
Drug Alias Nametrastuzumab-rezetecan艾维达SHR-A1811
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable thioether linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SHR9265 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2DNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[19] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryUnited StatesTaiwanAustralia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFudan UniversityGlenmark Specialty SaChina Medical University, China +[8] 
Inactive CompaniesHenan Provincial Cancer HospitalBeijing GoBroad HospitalTumor Research Institute Chinese Academy Of Medical Sciences +[4] 
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[18] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A